Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Next Previous
X
Search
Trial Profile

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR
  • Sponsors TearClear

    • Most Recent Events

    • 29 Sep 2022 According to a TearClear media release, the company to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) in the first quarter of 2023, based on data from this trial.
    • 29 Sep 2022 Results published in the TearClear Media Release.
    • 29 Sep 2022 Primary endpoint (Primary efficacy endpoint is the difference in mean change from baseline (CFB) in IOP) has been met, according to a TearClear media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top